The Competition Commission of India has cleared a change of control at one of the larger private hospital networks in south and west India, approving the takeover of a chain running close to 4,800 beds across 28 hospitals and units by a vehicle backed by the private equity giant KKR. The clearance was recorded in a press release dated October 22, 2026, with the Commission itself having announced the outcome a day earlier.
The buyer is Maybach Asia Holdings II Pte. Ltd., a special purpose vehicle that does not run any business of its own. It exists only to carry out this acquisition, and it sits indirectly under investment funds, vehicles and accounts that subsidiaries of KKR & Co. Inc. advise and manage. The target, Sahrudaya Health Care Private Limited, operates a multi-specialty hospital network directly and through its own subsidiaries, covering more than 80 clinical specialties across its facilities. The approval covers the acquisition of the entire equity share capital of Sahrudaya, not a partial or minority stake.
Under Section 6 of the Competition Act, 2002, a combination crossing the prescribed asset or turnover thresholds cannot be given effect to before the Commission has cleared it. Section 31 then lays out the Commission's choices once a notified combination comes up for review: approve it as filed, approve it subject to modifications, or, where it forms a prima facie opinion that the deal is likely to cause an appreciable adverse effect on competition in India, direct a fuller Phase II investigation. The Commission went with the first of these options here, approving the combination under Section 31(1) without recording any stated objection to the structure the parties had filed.
What has not yet followed is the Commission's reasoning. Its settled practice in combination matters is to put out the headline outcome first and release a fuller order some weeks after, once it has been finalised and cleared for publication internally. For a deal of this size, that later order is likely to matter to practitioners well beyond the two parties, since it should set out how the Commission defined the relevant market for multi-specialty hospital services in the regions where Sahrudaya's facilities sit, and whether it examined any overlap with other hospital assets that KKR or its affiliated funds may hold elsewhere in India.
Hospital consolidation has become one of the more active areas of combination filing before the Commission over the past few years, as private equity funds and strategic acquirers continue buying up stand-alone hospitals and smaller regional chains to build larger networks with more bargaining power over insurers, equipment vendors and staffing. Deals of this kind tend to clear without a Phase II reference where the target's bed capacity and geographic spread do not create an obvious overlap with assets the acquirer already controls, and the absence of any publicised competition concern in this case points that way, though the point will only be settled once the fuller order comes out.
No report on the approval disclosed the price Maybach Asia is paying for Sahrudaya, and nothing in the Commission's own announcement suggests that figure forms part of what it reviewed beyond the structure of the combination itself. Deal value is, in any case, not the test the Competition Act applies at the merger control stage. The thresholds in Section 5 of the Act turn on the assets and turnover of the parties involved, which is why combinations of very different transaction sizes can face an identical notification and review process before the Commission.
For hospital operators and the funds backing them, the clearance is a reminder that the Commission's merger control timeline can move faster than the rest of a healthcare buyout's own closing conditions, so regulatory approval is rarely the last item left on a transaction checklist once a filing of this kind has been made. Lenders and co-investors structuring comparable hospital-network acquisitions will be watching the detailed order, when it comes, for how the Commission treats bed capacity and specialty overlap as proxies for market power in a sector where formal market share data is hard to come by.